Vivesto — Share Issue/Capital Change 2014

Mar 7, 2014

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, AUSTRALIA, CANADA, HONG KONG, JAPAN , NEW ZEALAND , SINGAPORE , SOUTH AFRICA ORTHE UNITED STATES OR IN ANY JURISDICTION IN WHICH THE DISTRIBUTION OF THIS RELEASE WOULD BE UNLAWFUL.

March 7,2014

PRESS RELEASE

Oasmia successful lycompletes private placement of approximately SEK 72million

Oasmia Pharmaceutical AB (publ) ( Oasmia or the Company ) today announces that it has completed a private placement of 3,800,000 new shares, providing the Company with approximately SEK 72million before transaction related costs .

The private placement, which was announced on March 6,2014, has allowed Oasmia to place 3,800,000 new shares with international institutional investors and qualified investors in Sweden at a price of SEK 19per share through an accelerated book building procedure.

The proceeds from the Private Placement are intended to strengthen th e working capital as well asfinance the continued operations and further development of additional human and veterinary products based on the XR -17 technology.

For the purpose of the private placement, the Board of Directors of Oasmia has resolved, pursua nt to the authorization granted by the annual general meeting held on September 30, 2013, on a directed issue of 3,800,000 new shares. Thereason for deviatin gfrom the shareholders preferential rights by conducting a directed new share issue is to broaden the shareholder base.

Through the issue, the number of shares in Oasmia increases by 3,800,000 from81,772,330 to 85,572,330 and the share capital increases by SEK 380,000 from SEK 8,177,233 to SEK 8,557,233 . The new issue results in an equity dilution of approximately 4percent after completed issue. A large existing shareholder has undertaken to temporarily lend the number of shares required to facilitate prompt delivery of the new shares .

Carnegie Investme nt Bank is acting as manager andsole bookrunner.

The information above has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published on March 7,2014 at08.00amCET.

For more information, please contact: Mikael Widell, Vice President Communications Mobile: +46 70 311 99 60 E-mail: mikael.widell@oasmia.com

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY JURISDICTION IN WHICH THE DISTRIBUTION OF THIS RELEASE WOULD BE UNLAWFUL.

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary inhouse research and company patents. Oasmia's shares, ISIN SE0000722365, are listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX).

IMPORTANT INFORMATION

Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the constituent information in accordance with the rules and regulations prevailing in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Oasmia Pharmaceutical AB (publ) securities in any jurisdiction, neither from Oasmia Pharmaceutical AB (publ), Carnegie Investment Bank AB (publ) nor anyone else.